Ergothioneine-based telomere defense ingredient for healthy aging and longevity

Overview

Ergothioneine is a naturally occurring amino acid with potent antioxidant and cytoprotective properties, uniquely transported into cells and mitochondria via a specialized transporter (OCTN1). Blue California's branded ingredient, ErgoActive ergothioneine, is produced through proprietary precision fermentation, delivering a clean, sustainable, and high-purity ingredient suitable for global commercialization. The proposed solution positions ergothioneine as a telomere defense ingredient that addresses key hallmarks of aging, including oxidative stress, inflammation, and DNA damage, while supporting telomerase activity and preserving telomere length.

This ingredient is designed for partners in the dietary supplement, functional food and beverage, personal care, and cognitive health markets who seek scientifically validated, branded ingredients for healthy aging and longevity product lines. Ergothioneine has demonstrated longevity extension effects in animal models and is supported by association studies linking low ergothioneine levels to dementia risk, making it relevant for cognitive support formulations.

Technical specifications

Mechanisms of telomere defense:

• Combats inflammation and oxidative stress at the cellular and mitochondrial level
• Increases telomerase activity within 24 hours of treatment
• Preserves DNA integrity and supports DNA/RNA epigenetic regulation
• Modulates Sirtuin pathways associated with longevity

Validated effects on telomere length:

• In vitro study in human fibroblasts under oxidative conditions showed prevention of telomere shortening, longer median and 20th percentile telomere length versus controls, reduced proportion of short telomeres (<3 kbp) after 8 weeks, and decreased telomere shortening rate
• Longevity extension demonstrated in Drosophila models across diverse genetic backgrounds and both sexes

Product specifications:

• Available in dosage forms studied clinically at 10 mg/day, 25 mg/day, and 80 mg/day
• Produced via proprietary precision fermentation and bioconversion processes
• Supported by a vertically integrated supply chain ensuring quality and regulatory compliance
• Compatible with microencapsulation delivery systems for enhanced formulation flexibility

Research infrastructure:

• Double-blinded clinical trial in healthy adults ages 55-79 evaluating 10 mg/day and 25 mg/day versus placebo for 16 weeks, with telomere length as a secondary endpoint
• Additional completed double-blinded trial examining 80 mg/day for immune function outcomes, with biobanked blood samples available for telomere analysis
• Established collaborations with academic key opinion leaders and telomere analysis specialists

Technology readiness level

ErgoActive ergothioneine is at an advanced stage of commercial readiness. The ingredient has been validated in vitro for its direct effects on telomere length and telomerase activity, and clinical validation is ongoing through multiple double-blinded human trials. An association between ergothioneine levels and dementia risk has been established through observational studies, and longevity effects have been demonstrated in animal models. The ingredient is commercially available with regulatory compliance support for global markets. Blue California is actively seeking collaboration to define the next phase of clinical research and align telomere defense research with strategic business and scientific goals.